Predicting heart disease in patients with chronic kidney disease in Poland
Cardiovascular Disease in Patients With Chronic Kidney Disease: Polish Kidney- Heart Project
Medical University of Silesia · NCT06083168
This study is trying to see if collecting health data from people with chronic kidney disease in Poland can help predict heart problems and other related issues over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Silesia (other) |
| Locations | 2 sites (Olsztyn and 1 other locations) |
| Trial ID | NCT06083168 on ClinicalTrials.gov |
What this trial studies
This observational longitudinal study aims to collect demographic, laboratory, and clinical data from patients with chronic kidney disease (CKD) in Poland to predict the onset of cardiovascular disease and related events. The study will utilize machine learning and artificial intelligence to analyze the data collected from two academic centers over a period of 10 years. Patients will receive annual follow-ups via telephone and on-site health checks to monitor their health outcomes, including cardiovascular events and progression of kidney disease. A subgroup analysis will focus on patients with diabetes and CKD.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with chronic kidney disease, characterized by an eGFR of less than 60 ml/min/1.73 m2 or elevated urine albumin creatinine ratio.
Not a fit: Patients who are terminally ill with cancer or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction and management of cardiovascular risks in patients with chronic kidney disease.
How similar studies have performed: Other studies have shown success in using machine learning approaches to predict cardiovascular events in patients with chronic kidney disease, making this approach promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * CKD defined as estimated glomerular filtration rate (eGFR) \< 60ml/min/1.73 m2 and/or urine albumin creatinine ratio ( UACR) \> 30 mg/g lasting at least 3 months * CKD regardless of eGFR/albuminuria when documented otherwise (by means of imaging, renal biopsy result, genetic background, etc) Exclusion Criteria: * Death during hospital stay * Terminal stage of cancer * Lack of an informed consent
Where this trial is running
Olsztyn and 1 other locations
- Wojewódzki Szpital Specjalistyczny w Olsztynie — Olsztyn, Poland (RECRUITING)
- Samodzielny Publiczny Szpital Kliniczny Nr 1 im. prof. Stanisława Szyszko Śląskiego Uniwersytetu Medycznego w Katowicach — Zabrze, Poland (RECRUITING)
Study contacts
- Principal investigator: Katarzyna Nabrdalik, assoc. Prof — Medical University of Silesia
- Study coordinator: Katarzyna Nabrdalik, assoc. Prof
- Email: knabrdalik@sum.edu.pl
- Phone: 0048323704438
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Kidney Disease, Cardiovascular Diseases, chronic kidney disease, cardiovascular disease, artificial inteligence, predictors